On Tuesday, U.S. stocks experienced a positive trading session. The Dow Jones Industrial Average climbed over 480 points, marking a 0.99% increase to 49,462.08. The NASDAQ also saw gains, rising 0.65% to 23,547.17, while the S&P 500 increased by 0.62% to 6,944.82.These are the top stocks that gained the attention of retail traders and investors throughout the day.SanDisk Corporation (NASDAQ:SNDK)SanDisk shares soared by 27.56%, closing at $349.63. The stock reached an intraday high of $352 and a low of $288 ...

After turning in a strong performance to kick off the first full trading week of the new year, stocks saw further upside during trading on Tuesday. With the continued upward move, the Dow and the S&P 500 reached new record closing highs.The major averages ended the day just off their highs of the session. The Dow jumped 484.90 points or 1.0 percent to 49,462.08, the Nasdaq climbed 151.35 points or 0.7 percent to 23,547.17 and the S&P 500 rose 42.77 points or 0.6 percent to 6,944.82.The Dow benefitted from ...

The "Dogs of the Dow†strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow's perfo... ...

Core Insights - Amgen is developing MariTide, a late-stage obesity candidate, to compete with Eli Lilly and Novo Nordisk in the GLP-1 therapy market [1] - MariTide's long-acting profile allows for monthly or less frequent dosing, potentially improving patient adherence compared to weekly injectable options [2] - The drug is being evaluated in pivotal studies for obesity and other cardiometabolic conditions, with strong enrollment interest [3][4] Group 1: Product Development and Market Position - MariTide is part of Amgen's MARITIME phase III program, focusing on obesity and related cardiometabolic indications [1][3] - The drug has shown predictable and sustained weight loss in earlier studies, positioning it as a convenient long-term treatment option [2] - Enrollment for MARITIME-1 and MARITIME-2 studies has been completed with approximately 5,000 patients participating [3] Group 2: Competitive Landscape - Novo Nordisk has received FDA approval for an oral version of Wegovy, enhancing competition in the obesity treatment market [5] - Eli Lilly is also advancing its oral obesity candidate, orforglipron, with a potential launch next year [6] - Both market leaders continue to invest in next-generation therapies, indicating a robust competitive environment [7][8] Group 3: Financial Performance and Valuation - Amgen's shares have outperformed the industry year to date, reflecting positive market sentiment [9] - The company is trading at a P/E ratio of 15.20, which is below the industry average of 17.56, indicating a potential valuation opportunity [12] - EPS estimates for 2025 and 2026 have increased in the past 60 days, suggesting positive growth expectations [14]

GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the cheap penny stocks to invest in. On December 18, Morgan Stanley lowered the firm’s price target on GoodRx to $4 from $5 and kept an Equal Weight rating on the shares. In a 2026 outlook for the Healthcare Services sector, the firm highlighted a strong environment for market-beating returns within healthcare tech and provider stocks. In contrast, Morgan Stanley remains cautious on managed care and noted that after a weak 2025, the subsector continues to face a ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

Key Takeaways AMGN agreed to lower U.S. drug prices, align them with other developed markets and offer deep DTC discounts.AMGN expanded its AmgenNow program to Repatha, Aimovig and Amjevita with discounts of up to 80%.Amgen plans $2.5B in U.S. manufacturing and R&D investments tied to tariff exemptions.Amgen (AMGN) recently signed a landmark agreement with the Trump administration to lower drug prices in the United States.Through this deal, Amgen addresses the two major concerns that have plagued Big Pharma ...

Key Takeaways NVO leans on GLP-1 leadership, with Ozempic, Wegovy and Rybelsus driving growth but facing rising competition.AMGN benefits from diversification, with oncology, rare disease, biosimilars, and obesity studies underway.NVO shares fell sharply over six months, while AMGN stock gained as earnings estimates trended higher.Both Novo Nordisk (NVO) and Amgen (AMGN) are large-cap, innovation-driven healthcare leaders with global scale, strong balance sheets, and a track record of turning scientific bre ...

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent ne ...